Home
About
Leadership
Medical Advisory Board (AC5)
Scientific & Clinical Advisors
Corporate Mission
Products
Ordering Information
Intellectual Property
AC5 Advanced Wound System
Technology
Platform
Preclinical Data
Clinical Data
Pipeline
Pipeline Opportunity
Investors
Investor Relations
IR Overview
News
Press Releases
IR Calendar
Presentations
Interviews
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Governance Documents
Contact
Home
Investors
News
Press Releases
Investors
Overview
News
Press Releases
IR Calendar
Presentations
Interviews
Stock Data
SEC Filings
Corporate Governance
Press Releases
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
04/25/23
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)
04/5/23
Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect
03/9/23
Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services
03/7/23
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities
01/18/23
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
01/17/23
Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
12/5/22
The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System
10/18/22
Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall
10/11/22
Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
09/23/22
Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program
09/20/22
Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)
09/16/22
Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange
09/7/22
Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System
09/1/22
Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System
07/7/22
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing
06/22/22
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel
05/9/22
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring
04/13/22
Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring
04/4/22
Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring
03/14/22
Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System
01/6/22
Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
01/4/22
Arch Therapeutics Announces Appointment of Guy Fish to the Board
12/13/21
Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
12/1/21
Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
11/1/21
Arch Therapeutics Presents AC5® Advanced Wound System During Innovation Spotlight at 2021 Symposium on Advanced Wound Care (SAWC)
10/25/21
Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) Fall
10/18/21
Arch Therapeutics Launches Experts in Wound Care Program
10/13/21
Arch Therapeutics Provides Corporate Update
10/6/21
Arch Therapeutics to Present at the LD Micro Main Event
10/4/21
Arch Therapeutics Launches Coverage and Reimbursement Pilot
09/30/21
Arch Therapeutics Announces Appointment of Larry Hicks to the Board
09/2/21
Arch Therapeutics Partners with Lovell Government Services to Expand Distribution Capabilities
07/12/21
Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of Sales
07/7/21
Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021
06/2/21
Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021
05/10/21
Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS)
05/3/21
Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer
04/27/21
Arch Therapeutics to Present AC5® Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC)
04/19/21
Arch Therapeutics Provides Corporate Update on Commercialization Efforts and Clinical Results
03/2/21
Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021
02/18/21
Arch Therapeutics Announces Closing of $6.9 Million Private Placement
02/12/21
Arch Therapeutics Announces $6.9 Million Private Placement
01/5/21
Arch Therapeutics to Present at the H.C. Wainwright BioConnect Conference, January 11 - 14, 2021
01/4/21
Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.
12/11/20
Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference
11/10/20
Arch Raises Approximately $1.1 Million with Convertible Note Issuance
11/9/20
Arch Therapeutics’ AC5 Advanced Wound System Presented at the 2020 Symposium on Advanced Wound Care (SAWC) Fall
10/22/20
Arch Therapeutics, Inc. to Present at the Virtual Investor KOL Roundtable
10/14/20
Arch Therapeutics Announces Presentations on AC5 Advanced Wound System at the 2020 Symposium on Advanced Wound Care (SAWC) Fall
09/10/20
Arch Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 12 PM ET
08/26/20
Arch Therapeutics to Present at The LD 500 Virtual Conference on Tuesday, September 1 at 1 PM ET
08/11/20
Arch Therapeutics Novel Self-Assembling Agent, AC5-GTM, for Use in Endoscopic Procedures was Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting
08/7/20
Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Virtual 2020 Annual Meeting Starting August 11, 2020
06/8/20
Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series
06/5/20
Arch Raises $1.4 Million with Convertible Note Issuance and Warrant Reprice
06/3/20
Arch Therapeutics to Provide Corporate Update at the Virtual Summer Summit
04/13/20
Arch Therapeutics Receives CE Mark Approval for AC5™ Topical Hemostat in Europe
03/23/20
Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain
03/18/20
Arch Therapeutics, Inc. to Present at the New York City based Investor Summit on March 25th-26th
03/4/20
Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting on April 2, 2020
03/2/20
Arch Therapeutics to Provide Corporate Update at the 2020 LD Micro Virtual Investor Conference
01/8/20
Arch Therapeutics to Provide Corporate Update at Biotech Showcase™ 2020 on January 13th, 2020
10/17/19
Arch Therapeutics Announces $2.5 Million Registered Direct Offering
10/7/19
Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
09/3/19
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference
08/5/19
Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
05/30/19
Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational
05/13/19
Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering
04/24/19
Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video
03/11/19
Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference
02/5/19
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
12/20/18
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
12/17/18
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
12/6/18
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
12/4/18
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
11/28/18
Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe
11/26/18
Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018
10/1/18
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel
09/25/18
Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018
09/5/18
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
08/28/18
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018
08/16/18
Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018
07/20/18
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
06/29/18
Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering
06/26/18
Arch Therapeutics Provides Skin Sensitization Study Status Update
06/15/18
Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study
05/15/18
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
05/8/18
Arch Therapeutics Provides Update on Study Initiation and 510(k)
03/12/18
Arch Therapeutics Provides Update on 510(k)
03/5/18
Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018
02/5/18
Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical Application
01/2/18
Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase™ 2018 Conference on January 8th, 2018
12/18/17
Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA
11/28/17
Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017
09/20/17
Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences
09/12/17
Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity
09/6/17
Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
07/25/17
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel
06/6/17
Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
05/22/17
Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
03/6/17
Arch Therapeutics to Provide Corporate Update at the 29th Annual Roth Conference on Monday, March 13, 2017
02/27/17
Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference
02/21/17
Arch Therapeutics, Inc. $6.1 Million Registered Direct Offering
02/16/17
Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)
02/8/17
Arch Therapeutics to Provide Corporate Updates at Two Conferences in New York, February 2017
02/2/17
Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics
01/23/17
Arch Therapeutics to Present at Noble Financial Capital Markets' Thirteenth Annual Equity Conference
01/5/17
Arch Therapeutics to Present at The Biotech Showcase(TM) 2017 Conference on January 10th, 2017
12/5/16
Arch Therapeutics to Present at 9th Annual LD Micro Main Event on December 7, 2016
10/31/16
Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study
10/11/16
Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016
09/15/16
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
09/12/16
Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
08/22/16
Arch Therapeutics Will Present 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
08/19/16
Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire
08/15/16
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
06/6/16
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
05/27/16
Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
05/16/16
Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics
05/10/16
Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides
04/26/16
Arch Therapeutics to Present at PIONEERS 2016 by Joseph Gunnar & Co. Thursday, May 5, 2016
04/25/16
Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides
04/11/16
Arch Therapeutics Announces Notice of Allowance for Method of Use Patent Covering Uses of Self-Assembling Peptides
04/5/16
Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling Peptides
03/22/16
Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in Humans
03/14/16
Arch Therapeutics Reports Favorable Results for AC5 Surgical Hemostatic Device in Biocompatibility Testing Required for CE Mark
03/10/16
Arch Therapeutics to Present at the 28th Annual Roth Capital Conference on Tuesday, March 15, 2016
03/9/16
Arch Therapeutics Receives ISO 13485 Certification for AC5
03/7/16
Arch Therapeutics Clinical Trial Actively Enrolling Patients and Providing Investigational Treatment
02/17/16
Arch Therapeutics to Present at the SeeThruEquity Annual Innovations Investor Conference in Miami, Florida on Monday, February 22, 2016
02/8/16
Arch Therapeutics to Present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Wednesday, February 10, 2016
02/3/16
Arch Therapeutics to Present at the BIO CEO & Investor Conference on Monday, February 8, 2016
01/4/16
Arch Therapeutics to Present at the Biotech Showcase(TM) 2016 Conference on January 12th 2016